ScripWhile the world’s pharma industry has increasingly connected with Chinese-developed me-too or fast-follower novel drugs over the past few years, AstraZeneca, which already has more than three decades
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli
ScripGoing global, including through licensing out deals, is the only approach for Chinese biotech companies to survive now and in the following decade. At least this was a key message from the China biote
In VivoThe 2023 pharmaceutical sales ranking of the top 100 Asian biopharma firms reveals a mix of company-specific and wider performance factors linked to both individual corporate fortunes and the changing